Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting (GlobeNewswire) - Jun 29, 2023 - P1 | N=18 | ReSPECT-LM (NCT05034497) | Sponsor: Plus Therapeutics | "Interim results from 10 patients in the Phase 1 trial show a single treatment with rhenium (186Re) obisbemeda decreased cerebrospinal fluid (CSF) tumor cell count and was well-tolerated in patients with LM. Rhenium (186Re) obisbemeda doses administered through an intraventricular catheter (Ommaya reservoir) showed prompt, complete and durable distribution throughout the CSF through Day 7. A single rhenium (186Re) obisbemeda administered dose between 6.6 mCi and 26.4 mCi achieved absorbed doses of up to 88.98 Gy to the ventricles and cranial subarachnoid space. Phase 1/Part B, for continued dose escalation (Cohorts 4-7), will open following review by the U.S. Food and Drug Administration, and repeated dosing will be explored. An expansion in Cohort 3 is currently enrolling eligible patients. A full update will be provided at the SNO/ASCO CNS Cancer Conference in August 10-12, 2023."
Enrollment status • P1 data • Brain Cancer • CNS Tumor • Oncology • Solid Tumor
|